These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 31939034)

  • 61. DNA Methylation of PITX2 and PANCR Is Prognostic for Overall Survival in Patients with Resected Adenocarcinomas of the Biliary Tract.
    Uhl B; Dietrich D; Branchi V; Semaan A; Schaefer P; Gevensleben H; Rostamzadeh B; Lingohr P; Schäfer N; Kalff JC; Kristiansen G; Matthaei H
    PLoS One; 2016; 11(10):e0165769. PubMed ID: 27798672
    [TBL] [Abstract][Full Text] [Related]  

  • 62. Multicenter validation of a score to predict prognosis after the development of HCC recurrence following liver transplantation.
    Goldaracena N; Mehta N; Scalera I; Sposito C; Atenafu EG; Yao FY; Muiesan P; Mazzaferro V; Sapisochin G
    HPB (Oxford); 2019 Jun; 21(6):731-738. PubMed ID: 30391218
    [TBL] [Abstract][Full Text] [Related]  

  • 63. Hyperfibrinogenemia predicts poor prognosis in patients with advanced biliary tract cancer.
    Li H; Zhao T; Ji X; Liang S; Wang Z; Yang Y; Yin J; Wang R
    Tumour Biol; 2016 Mar; 37(3):3535-42. PubMed ID: 26453118
    [TBL] [Abstract][Full Text] [Related]  

  • 64. Patterns and relevant factors of tumor recurrence for extrahepatic bile duct carcinoma after radical resection.
    Park SW; Park YS; Chung JB; Kang JK; Kim KS; Choi JS; Lee WJ; Kim BR; Song SY
    Hepatogastroenterology; 2004; 51(60):1612-8. PubMed ID: 15532789
    [TBL] [Abstract][Full Text] [Related]  

  • 65. Prognostic factors in patients with advanced biliary tract cancer receiving chemotherapy.
    Saisho T; Okusaka T; Ueno H; Morizane C; Okada S
    Hepatogastroenterology; 2005; 52(66):1654-8. PubMed ID: 16334750
    [TBL] [Abstract][Full Text] [Related]  

  • 66. Impact of multiple transarterial chemoembolization treatments on hepatocellular carcinoma for patients awaiting liver transplantation.
    Terzi E; Ray Kim W; Sanchez W; Charlton MR; Schmeltzer P; Gores GJ; Andrews JC; Smyrk TC; Heimbach JK
    Liver Transpl; 2015 Feb; 21(2):248-57. PubMed ID: 25371111
    [TBL] [Abstract][Full Text] [Related]  

  • 67. Risk factor analysis of locoregional recurrence after sublobar resection in patients with clinical stage IA non-small cell lung cancer.
    Koike T; Koike T; Yoshiya K; Tsuchida M; Toyabe S
    J Thorac Cardiovasc Surg; 2013 Aug; 146(2):372-8. PubMed ID: 23870323
    [TBL] [Abstract][Full Text] [Related]  

  • 68. Prognostic impact of tumoral and/or peri-tumoral stromal SPARC expressions after surgery in patients with biliary tract cancer.
    Nakashima S; Kobayashi S; Sakai D; Tomokuni A; Tomimaru Y; Hama N; Wada H; Kawamoto K; Marubashi S; Eguchi H; Matsuura N; Doki Y; Mori M; Nagano H
    J Surg Oncol; 2014 Dec; 110(8):1016-22. PubMed ID: 25155283
    [TBL] [Abstract][Full Text] [Related]  

  • 69. Liver resection as a bridge to transplantation for hepatocellular carcinoma on cirrhosis: a reasonable strategy?
    Adam R; Azoulay D; Castaing D; Eshkenazy R; Pascal G; Hashizume K; Samuel D; Bismuth H
    Ann Surg; 2003 Oct; 238(4):508-18; discussion 518-9. PubMed ID: 14530722
    [TBL] [Abstract][Full Text] [Related]  

  • 70. Repeat hepatectomy for patients with early and late recurrence of hepatocellular carcinoma: A multicenter propensity score matching analysis.
    Xing H; Sun LY; Yan WT; Quan B; Liang L; Li C; Zhou YH; Wang H; Zhong JH; Gu WM; Chen TH; Wang MD; Wu H; Pawlik TM; Lau WY; Wu MC; Shen F; Yang T
    Surgery; 2021 Apr; 169(4):911-920. PubMed ID: 31879090
    [TBL] [Abstract][Full Text] [Related]  

  • 71. Intensive Follow-Up Program and Oncological Outcomes of Biliary Tract Cancer Patients after Curative-Intent Surgery: A Twenty-Year Experience in a Single Tertiary Medical Center.
    Rizzo A; Carloni R; Frega G; Palloni A; Di Federico A; Ricci AD; De Luca R; Tavolari S; Brandi G
    Curr Oncol; 2022 Jul; 29(7):5084-5090. PubMed ID: 35877262
    [TBL] [Abstract][Full Text] [Related]  

  • 72. Efficacy of Preoperative Portal Vein Embolization Among Patients with Hepatocellular Carcinoma, Biliary Tract Cancer, and Colorectal Liver Metastases: A Comparative Study Based on Single-Center Experience of 319 Cases.
    Yamashita S; Sakamoto Y; Yamamoto S; Takemura N; Omichi K; Shinkawa H; Mori K; Kaneko J; Akamatsu N; Arita J; Hasegawa K; Kokudo N
    Ann Surg Oncol; 2017 Jun; 24(6):1557-1568. PubMed ID: 28188502
    [TBL] [Abstract][Full Text] [Related]  

  • 73. Activity and safety of RAD001 (everolimus) in patients affected by biliary tract cancer progressing after prior chemotherapy: a phase II ITMO study.
    Buzzoni R; Pusceddu S; Bajetta E; De Braud F; Platania M; Iannacone C; Cantore M; Mambrini A; Bertolini A; Alabiso O; Ciarlo A; Turco C; Mazzaferro V
    Ann Oncol; 2014 Aug; 25(8):1597-603. PubMed ID: 24827133
    [TBL] [Abstract][Full Text] [Related]  

  • 74. [Survival benefits of chemotherapy for unresectable biliary tract cancer--a multicenter retrospective analysis].
    Funakoshi A; Horiuchi H; Sakai T; Miyahara T; Muranaka T; Nakamura M; Mizumoto K; Ueki T; Taketomi A; Yamaguchi H; Sumii T; Ito T
    Gan To Kagaku Ryoho; 2010 Dec; 37(13):2875-9. PubMed ID: 21160263
    [TBL] [Abstract][Full Text] [Related]  

  • 75. Correction to: Proposed Definition for Oligometastatic Recurrence in Biliary Tract Cancer Based on Results of Locoregional Treatment: A Propensity-Score-Stratified Analysis.
    Morino K; Seo S; Yoh T; Fukumitsu K; Ishii T; Taura K; Morita S; Kaido T; Uemoto S
    Ann Surg Oncol; 2021 Dec; 28(Suppl 3):884. PubMed ID: 34152525
    [No Abstract]   [Full Text] [Related]  

  • 76. Integrating Machine Learning and Tumor Immune Signature to Predict Oncologic Outcomes in Resected Biliary Tract Cancer.
    Ji GW; Wang K; Xia YX; Wang JS; Wang XH; Li XC
    Ann Surg Oncol; 2021 Jul; 28(7):4018-4029. PubMed ID: 33230745
    [TBL] [Abstract][Full Text] [Related]  

  • 77. A critical appraisal of the potential benefit of post-operative structured follow-up after resection for biliary tract cancer.
    Nooijen LE; van der Snee L; Ten Haaft B; Kazemier G; Klümpen HJ; Bridgewater J; Primrose J; Erdmann J
    HPB (Oxford); 2024 Feb; 26(2):179-187. PubMed ID: 37891150
    [TBL] [Abstract][Full Text] [Related]  

  • 78. ASO Author Reflections: Defining Oligometastatic Recurrence in Biliary Tract Cancer.
    Morino K; Yoh T; Seo S
    Ann Surg Oncol; 2020 Jun; 27(6):1918. PubMed ID: 32170479
    [No Abstract]   [Full Text] [Related]  

  • 79. Molecular Differences With Therapeutic Implications in Early-Onset Compared With Average-Onset Biliary Tract Cancers.
    Jayakrishnan T; Baca Y; Xiu J; Patel M; Weinberg BA; Lou E; Datta J; Khushman M; Gulhati P; Goel S; Biachi de Castria T; Florou V; Nair KG; Kamath SD; Khorana AA
    JCO Precis Oncol; 2024 Aug; 8():e2400138. PubMed ID: 39102632
    [TBL] [Abstract][Full Text] [Related]  

  • 80. Morbidity after left trisectionectomy for hepato-biliary malignancies: An analysis of the National Clinical Database of Japan.
    Terasaki F; Hirakawa S; Tachimori H; Sugiura T; Nanashima A; Komatsu S; Miyata H; Kakeji Y; Kitagawa Y; Nakamura M; Endo I
    J Hepatobiliary Pancreat Sci; 2023 Dec; 30(12):1304-1315. PubMed ID: 37750342
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.